Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy

[1]  C. Ohyama,et al.  Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy , 2022, Scientific Reports.

[2]  M. Shiota,et al.  Validation of models predicting lymph node involvement probability in patients with prostate cancer , 2022, International journal of urology : official journal of the Japanese Urological Association.

[3]  Warren C. Grant,et al.  Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol , 2021, The Lancet.

[4]  V. Laudone,et al.  Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. , 2021, European urology oncology.

[5]  J. Eastham,et al.  Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. , 2021, European urology oncology.

[6]  J. Marenco,et al.  Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy , 2021, International journal of urology : official journal of the Japanese Urological Association.

[7]  S. Faraj,et al.  Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. , 2020, European urology.

[8]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[9]  K. Matsushita,et al.  Impact of indocyanine green‐guided extended pelvic lymph node dissection during robot‐assisted radical prostatectomy , 2020, International journal of urology : official journal of the Japanese Urological Association.

[10]  P. Esteban Delgado,et al.  A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RISK FACTORS FOR REBLEEDING FOLLOWING DEVICE-ASSISTED ENTEROSCOPY THERAPY OF SMALL-BOWEL VASCULAR LESIONS , 2020, Endoscopy.

[11]  Y. Akagi,et al.  Long‐term follow‐up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212) , 2020, The British journal of surgery.

[12]  P. Kantoff,et al.  PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC). , 2019, Journal of Clinical Oncology.

[13]  M. Shiota,et al.  Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer , 2019, Urologia Internationalis.

[14]  P. Albers,et al.  Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. , 2019, European urology.

[15]  Jae-Weon Kim,et al.  A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms , 2019, The New England journal of medicine.

[16]  M. Amin,et al.  Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. , 2018, European Urology.

[17]  Ronald C. Chen,et al.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options , 2018, The Journal of urology.

[18]  H. G. van der Poel,et al.  The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. , 2017, European urology.

[19]  K. Haustermans,et al.  The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer , 2017, Prostate Cancer and Prostatic Diseases.

[20]  T. Habuchi,et al.  The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis , 2016, Medical Oncology.

[21]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[22]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[23]  C. Pavlovich,et al.  Pelvic node dissection in prostate cancer: extended, limited, or not at all? , 2010, Current opinion in urology.

[24]  K. Allen,et al.  Results of Prospective Randomized Trials , 2007 .

[25]  B. Guillonneau,et al.  Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. , 2007, The Journal of urology.

[26]  K. Campbell,et al.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinomad—part 3: Update on 5-year survival , 2005, Journal of Gastrointestinal Surgery.

[27]  B. Trock,et al.  Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. , 2004, The Journal of urology.

[28]  Paul Fockens,et al.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. , 2002, The New England journal of medicine.

[29]  Jong-Hyeon Jeong,et al.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. , 2002, The New England journal of medicine.

[30]  D. Wood,et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.

[31]  M. Gleave,et al.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. , 2001, The Journal of urology.

[32]  D. Gouma,et al.  Extended lymph-node dissection for gastric cancer. , 1999, The New England journal of medicine.

[33]  J. Izbicki,et al.  Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. , 1998, Annals of surgery.

[34]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.